Japan’s Cosmo Bio to Distribute Aviva’s Electrophysiology Products and Services
Aviva Biosciences this week said that it has selected Cosmo Bio as its distributor for the Japanese territory.
Cosmo Bio will provide custom electrophysiological services, including Aviva’s HergExpress ion channel cardiac safety assessment service.
Aviva said that Cosmo Bio’s human heart tissue arrays and human cardiac myocyte electrophysiology capabilities complement Aviva’s automated electrophysiology services and ion channel cell lines.
Based in San Diego, Aviva Biosciences primarily markets biochips for drug discovery, including the disposable 16-channel version of its SealChip for Molecular Devices’ PatchXpress platform.
Millipore Posts 38-Percent Rise in Q3 Revenue as Profit Slips 35 Percent
Millipore this week said third-quarter revenues increased 38 percent as R&D spending rose 31 percent and profits slid 35 percent.
Total receipts for the three months ended Sept. 30 increased to $330.1 million from $239.6 million year over year. Compared with the third quarter of 2005, sales in the company’s Bioprocess segment were up 34 percent to $195 million, while its Bioscience segment gained 44 percent with sales of $135 million.
R&D spending increased to $24.6 million from $18.9 million year over year.
The company said profits declined to $14.8 million from $22.9 million in the year-ago period.
Millipore said it had around $91.4 million in cash and cash equivalents as of Sept. 30.
Becton Dickinson Posts 8-Percent Rise in Fiscal Q4 Revenue as Profit Increases 17 Percent
Becton Dickinson this week said that fiscal fourth-quarter revenues were up almost 8 percent and profits were up 17 percent.
BD said total receipts for the three months ended Sept. 30 increased to $1.5 billion from $1.4 billion year over year.
R&D spending for the period increased to $83.6 million from $76.6 million.
The company said net income for the period increased to $174 million from $149 million last year.
Becton Dickinson did not report its balance sheet for the quarter.
Beckman Coulter Posts 6-Percent Rise in Q3 Revenue as Profit Soars 31 Percent
Beckman Coulter this week said that third-quarter revenue increased 6.1 percent as profits jumped 31 percent.
Total receipts for the three months ended Sept. 30 increased to $631.2 million from $593.4 million year over year.
Beckman Coulter attributed the good numbers to increased revenues on consumables, particularly in Europe and, to a lesser extent, in the Far East.
R&D costs in the quarter increased 57 percent to $81 million year over year.
Net income for the quarter was up to $47.5 million, compared with $36.2 million during the same period last year.
Beckman Coulter said it had around $69.1 million in cash and cash equivalents as of Sept. 30.
PerkinElmer Q3 Receipts Grow 7 Percent, but Profits Sink 7 Percent
PerkinElmer this week said that revenue for the third quarter increased 7 percent while profits fell 7 percent.
Total receipts for the three months ended Sept. 30 increased to $387 million from $360 million year over year.
Revenue from its life and analytical sciences division grew to $284 million from $259 million year over year.
The company spent $24.8 million on research and development in the quarter, up $3 million from last year.
Income declined to $29.7 million from $31.8 million in the third quarter of 2005.
PerkinElmer said it had around $207 million in cash and cash equivalents, and around $7.5 million in marketable securities and investments as of Sept. 30.
Invitrogen’s Q3 Organic Revenues Up 3 Percent as Profit Turns to Loss
Invitrogen this week said that third-quarter revenues increased 7 percent while last year’s profit turned to a loss.
Total receipts for the three months ended Sept. 30 increased to $311 million from $290 million year over year. Revenue grew 3 percent organically.
The company’s Biodiscovery segment grew 2 percent while the Cell Culture Systems segment grew 4 percent.
The company spent $26.8 million on research and development, nearly the same amount as the previous year’s third quarter.
Invitrogen this period posted a net loss of $130 million compared to a profit of $24.million in the same quarter last year.
The company said the net loss was caused by a non-cash charge of $150 million “associated with a goodwill impairment” in its Cell Culture Systems division.
Invitrogen closed the quarter with around $512 million in cash and investments.